V-Bio Ventures
Venture capitalBrussels · Seed–Series B · 10 people tracked
Investment thesis
V-Bio Ventures backs companies developing innovative and transformational life science technologies with high societal and environmental impact. The firm focuses on therapeutics including drug discovery and development, sourcing deals from research institutions, entrepreneurial initiatives, and spin-outs. V-Bio leverages an extensive network and deep sector expertise to contribute beyond capital, aiming to be part of the core strategy of portfolio companies. The firm has a preferred partnership with VIB, a premier Belgian life science research institute, and maintains a geographic focus on European opportunities.
Source: firm website, verified Jul 21, 2026.
Team · 10 people
from the firm's websiteCo-founder of V-Bio Ventures with over 15 years of European venture capital experience in biopharmaceutical and pharmaceutical investments. She previously was a partner at Forbion Capital Partners and holds a PhD in Developmental Biology.
Joined V-Bio Ventures in 2020 and brings over 20 years of executive experience in finance and business across European biotechnology companies. She served as CFO during Merus' Nasdaq IPO and as CEO of Gadeta, managing funding rounds and strategic exits.
Co-founder of V-Bio Ventures with over 15 years in VC-backed life sciences companies as entrepreneur, consultant, and executive. He founded Fugeia (now owned by Cargill) and was VP of R&D at CropDesign, and previously held an academic position in plant biotechnology.
Partner at V-Bio Ventures since 2016 with over 12 years in life science venture business. She previously worked as analyst at Polytechnos Venture-Partners, CBO/CFO at Advitos, and senior investment manager at Ascenion managing the Spinnovator initiative.
Partner at V-Bio Ventures since 2016 with a PhD in molecular biology and research experience at VIB/UGent, the John Innes Centre, and Harvard Medical School. He previously was a senior analyst at Candriam Investors Group evaluating early-stage listed biotech companies.
Joined V-Bio Ventures as Venture Partner in February 2025 with experience spanning healthcare as entrepreneur, investor, and corporate innovator. He previously worked at Merck KGaA driving external innovation in healthcare technologies and modalities, and at Forbion in venture capital.
Ph.D. scientist with over 25 years of leadership in non-clinical and translational sciences at global pharmaceutical companies. Most recently Senior Scientific Director at AbbVie leading DMPK and bioanalysis groups across neuroscience, immunology, and oncology, bringing expertise in preclinical development, quantitative pharmacology, and team management.
Medical doctor with over 25 years of experience in clinical development, pharmacovigilance, and medical affairs across biotech and pharma. Previously served as CMO at PPRS SAS and held leadership roles at Genethon, Ipsen, AstraZeneca, and the French Health Products Safety Agency, with therapeutic focus in immunology, CNS, and rare diseases.
Finance Manager at V-Bio Ventures since its inception in 2015 with extensive experience in venture capital financial management and biotech companies. He previously worked as an independent financial consultant and at Arthur Andersen in business process management.
Member of V-Bio Ventures' strategic advisory board with over 20 years in venture capital focused on biotechnology and medtech. He co-founded Life Sciences Partners and Innovation Industries, and previously founded U-Gene Research, which was sold to Kendle.
Frequently asked questions
- What stage does V-Bio Ventures invest at?
- V-Bio Ventures invests at the Seed, Series A, Series B stages.
- What sectors does V-Bio Ventures focus on?
- V-Bio Ventures focuses on Biotech, Medical Devices.
- Where is V-Bio Ventures located?
- V-Bio Ventures is headquartered in Brussels, BE.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.